Henshaw Capital LLC decreased its position in Astrazeneca Plc (NYSE:AZN – Free Report) by 37.3% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 5,880 shares of the company’s stock after selling 3,500 shares during the period. Henshaw Capital LLC’s holdings in Astrazeneca were worth $1,160,000 as of its most recent SEC filing.
Several other hedge funds also recently made changes to their positions in the company. Mascoma Wealth Management LLC bought a new stake in Astrazeneca during the 1st quarter valued at $26,000. MV Capital Management Inc. purchased a new stake in Astrazeneca during the 4th quarter valued at $26,000. Reflection Asset Management bought a new stake in Astrazeneca in the 4th quarter worth $31,000. Resources Management Corp CT ADV bought a new stake in Astrazeneca in the 1st quarter worth $35,000. Finally, Raleigh Capital Management Inc. purchased a new position in shares of Astrazeneca in the first quarter valued at about $38,000. 20.35% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on AZN. Wall Street Zen downgraded shares of Astrazeneca from a “buy” rating to a “hold” rating in a research note on Saturday. The Goldman Sachs Group reissued a “buy” rating on shares of Astrazeneca in a research note on Wednesday, July 1st. Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a report on Friday, June 26th. Bank of America reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday, July 1st. Finally, Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a report on Tuesday, June 30th. Twelve equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $211.00.
Astrazeneca Trading Down 0.9%
Shares of NYSE AZN opened at $169.77 on Friday. Astrazeneca Plc has a 1 year low of $145.79 and a 1 year high of $212.71. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.89 and a quick ratio of 0.71. The firm has a 50-day moving average of $179.02 and a 200 day moving average of $187.80. The stock has a market cap of $263.30 billion, a P/E ratio of 25.38, a price-to-earnings-growth ratio of 1.47 and a beta of 0.24.
Astrazeneca (NYSE:AZN – Get Free Report) last announced its quarterly earnings data on Monday, July 27th. The company reported $2.63 earnings per share for the quarter, topping analysts’ consensus estimates of $2.50 by $0.13. Astrazeneca had a net margin of 17.02% and a return on equity of 31.45%. The business had revenue of $15.38 billion for the quarter, compared to analysts’ expectations of $15.44 billion. During the same quarter in the prior year, the company earned $2.17 earnings per share. The business’s revenue was up 6.4% compared to the same quarter last year. As a group, sell-side analysts expect that Astrazeneca Plc will post 10.22 EPS for the current fiscal year.
Astrazeneca Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
See Also
- Five stocks we like better than Astrazeneca
- Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
